These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 34526102)

  • 1. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
    Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
    Front Immunol; 2021; 12():785091. PubMed ID: 35111155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
    Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
    Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.
    Yoshida T; Nakamoto T; Atsumi N; Ohe C; Sano T; Yasukochi Y; Tsuta K; Kinoshita H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1.
    Zhang WT; Liu TT; Wu M; Chen XC; Han L; Shi ZZ; Li YY; Li XY; Xu HX; Gong LK; Xu PH; Geng Y
    Acta Pharmacol Sin; 2021 Nov; 42(11):1921-1929. PubMed ID: 33633363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential.
    Liu XH; Qi LW; Alolga RN; Liu Q
    Int J Biol Sci; 2022; 18(1):292-300. PubMed ID: 34975333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
    Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
    Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
    Mariuzza RA; Shahid S; Karade SS
    J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.
    Qian Y; Sun Y; Shi P; Zhou X; Zhang Q; Dong Q; Jin S; Qiu L; Niu X; Zhou X; Zhao W; Wu Y; Zhai W; Gao Y
    Acta Pharm Sin B; 2024 Mar; 14(3):1150-1165. PubMed ID: 38486998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
    Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L
    J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
    Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
    Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
    Lecocq Q; Keyaerts M; Devoogdt N; Breckpot K
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of USP7 enhances CD8
    Sun LL; Zhao LN; Sun J; Yuan HF; Wang YF; Hou CY; Lv P; Zhang HH; Yang G; Zhang NN; Zhang XD; Lu W
    Acta Pharmacol Sin; 2024 Aug; 45(8):1686-1700. PubMed ID: 38589688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
    Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
    Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8
    Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J
    J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.